Key Points
- Director Thomas Kosasa bought 158,730 OneMedNet shares on June 12 for about $99,999.90 at $0.63 per share, increasing his direct holdings to 17,088,874 shares.
- Kosasa has been actively adding to his stake, with two earlier purchases in May and April totaling roughly $500,000 combined.
- OneMedNet’s stock was trading near $0.56 with a market cap of about $30.37 million, while analysts currently have an overall Sell rating on the shares.
OneMedNet Corporation (NASDAQ:ONMD - Get Free Report) Director Thomas Kosasa purchased 158,730 shares of the company's stock in a transaction that occurred on Friday, June 12th. The shares were acquired at an average cost of $0.63 per share, for a total transaction of $99,999.90. Following the completion of the transaction, the director directly owned 17,088,874 shares of the company's stock, valued at $10,765,990.62. This trade represents a 0.94% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.
Thomas Kosasa also recently made the following trade(s):
- On Monday, May 18th, Thomas Kosasa acquired 268,817 shares of OneMedNet stock. The shares were acquired at an average price of $0.93 per share, with a total value of $249,999.81.
- On Thursday, April 23rd, Thomas Kosasa acquired 280,898 shares of OneMedNet stock. The shares were acquired at an average price of $0.89 per share, with a total value of $249,999.22.
OneMedNet Price Performance
NASDAQ:ONMD opened at $0.56 on Tuesday. The stock has a market cap of $30.37 million, a PE ratio of -11.16 and a beta of 1.12. OneMedNet Corporation has a fifty-two week low of $0.31 and a fifty-two week high of $4.22. The stock's 50-day moving average is $0.87 and its two-hundred day moving average is $0.96.
OneMedNet (NASDAQ:ONMD - Get Free Report) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.04) earnings per share (EPS) for the quarter. The firm had revenue of $0.10 million for the quarter.
Institutional Investors Weigh In On OneMedNet
Several large investors have recently made changes to their positions in the company. Jane Street Group LLC acquired a new position in OneMedNet in the fourth quarter worth approximately $119,000. Exencial Wealth Advisors LLC lifted its stake in OneMedNet by 1.3% in the fourth quarter. Exencial Wealth Advisors LLC now owns 3,644,861 shares of the company's stock valued at $4,009,000 after acquiring an additional 45,401 shares during the last quarter. Virtu Financial LLC acquired a new stake in OneMedNet in the fourth quarter valued at approximately $48,000. State Street Corp grew its position in OneMedNet by 41.5% in the fourth quarter. State Street Corp now owns 116,700 shares of the company's stock worth $128,000 after acquiring an additional 34,200 shares in the last quarter. Finally, HRT Financial LP bought a new stake in OneMedNet in the fourth quarter worth approximately $32,000. Institutional investors own 0.95% of the company's stock.
Analysts Set New Price Targets
ONMD has been the subject of a number of research reports. Wall Street Zen lowered shares of OneMedNet from a "hold" rating to a "sell" rating in a research note on Saturday, May 23rd. Weiss Ratings reiterated a "sell (e+)" rating on shares of OneMedNet in a report on Monday, June 1st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock has an average rating of "Sell".
View Our Latest Stock Report on ONMD
About OneMedNet
(
Get Free Report)
OneMedNet Corporation provides clinical imaging solutions. It offers iRWD, a solution that utilizes AI to securely de-identify, search, and curate imaging data for its partner network consisting of medical and academic research institutions to generate progression in stages of medical research, discovery and diagnostics that span the field of life sciences. OneMedNet Corporation is based in Eden Prairie, Minnesota.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
